Closing the gap between access to and adoption of type 1 diabetes (T1D) therapies is a mission priority for Breakthrough T1D.
Our newly created Medical Affairs unit provides education and resources for the entire T1D community, from clinicians to people living with the condition, so that everyone impacted by T1D is empowered to make informed decisions about healthcare and emerging therapies.
Chris Dunn represents our efforts in action.
Chris is a parent to four children, two of whom live with T1D. Knowing the increased risk of T1D in immediate family members, Chris and her children without T1D participated in screening. In what she could only describe as “surreal,” Chris’ screening results revealed the presence of multiple T1D antibodies; further testing indicated she was in stage 2.
For decades, Breakthrough T1D funded discovery research, supported clinical development, and worked with regulators to bring Tzield—the first disease-modifying therapy for type 1 diabetes—to market. Tzield is available to people in stage 2 type 1 diabetes—like Chris—and can delay progression to stage 3, or clinical onset of T1D, for up to three years. This means potentially years without blood-sugar monitoring, insulin administration, and the fear of short- and long-term complications.
